LNP 3794
Alternative Names: BI-3011441; LNP-3794Latest Information Update: 28 May 2024
At a glance
- Originator Lupin
- Developer Boehringer Ingelheim; Lupin
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (PO)
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Japan (PO)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (PO)